Pancreatic Elastase Testing Market Share

On the basis of geographical analysis, the global pancreatic elastase testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to account for largest revenue share by 2036, impelled by improving healthcare infrastructure in the developing countries, along with growing prevalence of pancreatic cancer in the region.

North America Market Analysis

The pancreatic elastase testing market in the North America region is anticipated to gain a significant market share throughout the forecast period owing to the growing prevalence of chronic pancreatitis in the region. According to the data by the National Pancreas Foundation, the prevalence of chronic pancreatitis is 50 per 100,000 individuals in the United States, and is more common in men than women.

On the other hand, the pancreatic elastase testing market in Europe occupied the largest market share in 2021, owing to the presence of the advanced healthcare facilities, favorable health insurance and reimbursement policies, and high healthcare expenditure in the developed countries, such as, Germany, Switzerland, France, Sweden, Norway, and Denmark.

Frequently Asked Questions (FAQ)

The increasing prevalence of chronic pancreatitis is estimated to boost the market growth.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 â€“ 2031.

The lack of researchers and practitioners in pathological science is estimated to hamper the market growth.

The North America region is anticipated to provide more business opportunities over the forecast period owing to the growing prevalence of chronic pancreatitis in the region.

The major players in the market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., BIOMERIEUX PLC, Bioserv Diagnostics Gmbh, Novozymes A/S, AB Enzymes GmbH, and Buhlmann Diagnostics Corp.

Pancreatic Elastase Testing Market Share